ObjectiveTo describe the current situation of the prevalence of hepatic hydatidosis, analyze the clinical characteristics and treatment method of the disease, in order to provide scientific basis for personal treatment plans of hepatic hydatidosis. MethodThe clinical data of 121 patients with recurrent hepatic hydatidosis treated between July 2006 and December 2013 were analyzed retrospectively. The general information of hydatid disease of liver, mass of liver, clinical manifestations, laboratory test results, treatment method, effectiveness of the treatment during hospitalization, and follow-up results were collected and analyzed. ResultsMost of the patients were adults from Sichuan and Tibet, and the majority of them had no clear occupation or clear animal contact history and had not taken raw or fresh meat. Lesions in the right lobe occurred in 87 cases, accounting for 71.90%. Abdominal pain and distension were the main clinical manifestations. Twenty-five (20.66%) of these patients were associated with hepatic dysfunction, among whom 23 patients had mild hepatic dysfunction. Alpha-fetoprotein level was increased in one (0.83%) of these cases. A total of 119 of the 121 patients received surgical treatment (98.35%) and all the surgeries were successful. Follow-up results revealed that three of the patients had recurrence. ConclusionsHepatic hydatidosis is an epidemic mainly in the Tibetan district of the West of China. The disease mainly occurs in the right lobe of the liver, which mainly causes mile liver damage. Hepatocellular carcinoma has not been found in these cases. Surgery treatment is the main therapy for liver hydatidosis and may result in good effectiveness.
ObjectiveTo systematically review the relationship between skin rashes and efficacy of cetuximab. MethodsSuch databases as PubMed, EMbase, The Cochrane Library (Issue 1, 2013), CBM, CNKI and VIP were systemically searched to collect literature on relationship between the severity of skin rashes and efficacy of cetuximab published up to Aug. 2013. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data, and evaluated methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. ResultsA total of 32 studies involving 1 543 patients were included. The results of metaanalysis showed that:the efficacy of cetuximab in patients with skin rashes was significantly superior to patients without skin rashes (RR=1.53, 95%CI 1.23 to 1.91, P=0.000 2); in addition, the efficacy of cetuximab in patients with severe skin rashes was significantly superior to patients with mild skin rashes (RR=2.42, 95%CI 1.89 to 3.11, P<0.000 01). ConclusionSkin rashes are significantly associated with better efficacy of cetuximab.